Literature DB >> 11533020

Susceptibility testing with linezolid by different methods, in relation to published 'general breakpoints'.

D M Livermore, S Mushtaq, M Warner.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11533020     DOI: 10.1093/jac/48.3.452

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  6 in total

1.  Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis.

Authors:  Cornelia Buerger; Nele Plock; Pejman Dehghanyar; Christian Joukhadar; Charlotte Kloft
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

2.  Activities of Tedizolid and Linezolid Determined by the Reference Broth Microdilution Method against 3,032 Gram-Positive Bacterial Isolates Collected in Asia-Pacific, Eastern Europe, and Latin American Countries in 2014.

Authors:  Michael A Pfaller; Robert K Flamm; Ronald N Jones; David J Farrell; Rodrigo E Mendes
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

3.  In vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program.

Authors:  Deborah C Draghi; Daniel J Sheehan; Patricia Hogan; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

4.  Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model.

Authors:  Lauren M Boak; Jian Li; Craig R Rayner; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

5.  The Oxazolidinones.

Authors:  Gerald A. Evans
Journal:  Curr Infect Dis Rep       Date:  2002-02       Impact factor: 3.725

Review 6.  Newer treatment options for skin and soft tissue infections.

Authors:  Murugan Raghavan; Peter K Linden
Journal:  Drugs       Date:  2004       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.